Limited Partnership Viii Ho... Net Worth

The estimated Net Worth of Limited Partnership Viii Ho... is at least $2.1 Million dollars as of 20 October 2020. Limited Ho owns over 184,375 units of Tarsus Pharmaceuticals stock worth over $2,104,270 and over the last 4 years Limited sold TARS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Limited Ho TARS stock SEC Form 4 insiders trading

Limited has made over 1 trades of the Tarsus Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Limited bought 184,375 units of TARS stock worth $2,950,000 on 20 October 2020.

The largest trade Limited's ever made was buying 184,375 units of Tarsus Pharmaceuticals stock on 20 October 2020 worth over $2,950,000. On average, Limited trades about 184,375 units every 0 days since 2020. As of 20 October 2020 Limited still owns at least 66,172 units of Tarsus Pharmaceuticals stock.

You can see the complete history of Limited Ho stock trades at the bottom of the page.

What's Limited Ho's mailing address?

Limited's mailing address filed with the SEC is 5030 CAMPUS DRIVE, SUITE A, , NEWPORT BEACH, CA, 92660.

Insiders trading at Tarsus Pharmaceuticals

Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita..., and William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.

What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Complete history of Limited Ho stock trades at Tarsus Pharmaceuticals

Tarsus Pharmaceuticals executives and stock owners

Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Bobak R. Azamian M.D.,
  Co-Founder, Pres, CEO & Director
• Dr. Seshadri Neervannan Ph.D.,
  Chief Operating Officer
• Leonard M. Greenstein,
  Chief Financial Officer
• Kim Norman,
  Sr. Director of Fin.
• Michael Holdbrook,
  VP of Clinical Affairs
• Aziz Mottiwala,
  Chief Commercial Officer
• Dianne C. Whitfield,
  Chief HR Officer
• Matthew Rossen M.B.A.,
  VP of Marketing
• Dr. Bryan Wahl J.D., M.D.,
  Gen. Counsel
• David Nakasone,
  Head of Investor Relations
• Jeffrey S Farrow,
  See Remarks
• Scott W Morrison,
  Director
• Michael Ackermann,
  Director
• Jason E. Tester,
  Director
• Capital Ix, Llc Vivo Capita...,
  
• Life Sciences Ix, L.P.Fhmls...,
  
• Limited Partnership Viii Ho...,
  10% owner
• Jose M. Trevejo,
  CHIEF MEDICAL OFFICER
• Bryan Wahl,
  General Counsel
• Dianne C. Whitfield,
  Chief Human Resources Officer
• Leonard M. Greenstein,
  Chief Financial Officer
• Wendy L Yarno,
  Director
• Aziz Mottiwala,
  Chief Commercial Officer
• Mark J. Holdbrook,
  V.P., Clinical Affairs
• Investments, Lpwong Roderic...,
  
• Bhaskar Chaudhuri,
  Director
• Andrew D. Goldberg,
  Director
• Rosemary A Crane,
  Director
• Elizabeth Yeu Lin,
  Director
• Bobak R. Azamian,
  President/CEO and Board Chair
• William J Phd Link,